RBC Capital Maintains Sector Perform on Apogee Therapeutics, Raises Price Target to $97

Benzinga Newsdesk www.benzinga.com Positive 88.2%

Neg 0% Neu 0% Pos 88.2%

RBC Capital analyst Brian Abrahams maintains Apogee Therapeutics (NASDAQ:APGE) with a Sector Perform and raises the price target from $82 to $97.